India Pharma Outlook Team | Saturday, 18 July 2026
Novo Nordisk's latest regulatory success of Wegovy in India reinforces a broader shift in the pharmaceutical landscape.
Glucagon-like peptide-1 (GLP-1) therapies are evolving from weight-loss and diabetes medicines into multi-disease treatments.
The Central Drugs Standard Control Organization (CDSCO) has approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
The approval adds another indication to the popular drug's expanding portfolio. GLP-1 receptor agonists are now being explored for chronic metabolic conditions beyond obesity.
The approval also positions Wegovy as a key therapy for interconnected diseases, including cardiovascular disorders and liver disease.
Initially approved as a once-weekly treatment for chronic weight management, Wegovy has now steadily expanded its therapeutic footprint.
The latest Indian approval allows its use in adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis, alongside lifestyle modifications.
MASH is a severe and progressive liver disease caused by the build-up of excess fat in the liver. It leads to inflammation and scarring, known as fibrosis.
If left untreated, the disease can progress to cirrhosis, liver failure and other serious liver-related complications. MASH is closely associated with obesity, type 2 diabetes and other metabolic disorders.
As these conditions continue to rise, MASH is emerging as one of the major public health challenges worldwide. The approval is supported by findings from the first phase of the Phase 3 ESSENCE trial.
After 72 weeks of treatment, 37 percent of patients receiving semaglutide 2.4 mg achieved improvement in liver fibrosis without worsening steatohepatitis, compared with 22.5 percent in the placebo group.
Also Read: How Portfolio Strategy Drives Profitability in Pharma Markets
The MASH indication is the latest addition to Wegovy's expanding list of approved uses. It also reflects Novo Nordisk's strategy of extending semaglutide into multiple therapeutic areas.
Latest milestones for Wegovy include:
Collectively, these regulatory milestones have transformed Wegovy from a weight-loss medication into a diversified metabolic medicine. Today, its portfolio spans obesity, cardiovascular risk reduction and liver disease.
The Indian approval comes as GLP-1 therapies become central to the treatment of metabolic diseases. Rather than addressing obesity as an isolated condition, companies are increasingly positioning these medicines to target a broader spectrum of diseases driven by metabolic dysfunction.
For Novo Nordisk, the MASH approval not only opens a new treatment segment in India but also strengthens Wegovy's long-term commercial and clinical value. It gives the company an opportunity to expand into a high-growth market while addressing a significant unmet medical need.
As evidence continues to emerge from ongoing clinical studies, GLP-1 medicines appear poised to redefine treatment pathways across multiple chronic diseases. Wegovy's latest approval suggests that the future of these therapies may lie not only in helping patients lose weight, but also in tackling the wider spectrum of metabolic disorders that increasingly burden healthcare systems worldwide.
